Printer Friendly

FOLLOW-UP OF PATIENTS IN IMMUNOGEN'S CLINICAL TRIALS OF ONCOLYSIN B PRESENTED AT AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

 Data Continue to Indicate Substantial Reduction in Relapse Rate
 ST. LOUIS, Dec. 7 /PRNewswire/ -- Clinical results using ImmunoGen, Inc.'s (NASDAQ: IMGN) lead product, Oncolysin(R) B are being presented here today at the Annual Meeting of the American Society of Hematology (ASH). The data, of Phase I/II and Phase II trials in B-cell lymphoma patients who have undergone autologous bone marrow transplantation (ABMT), continue to show a substantial reduction in relapse rate as compared with that expected for ABMT patients.
 Commenting on the results from the ABMT studies, ImmunoGen Vice President and Chief Medical Officer Carol R. Epstein, M.D., states that "The data from our studies of Oncolysin B in ABMT patients indicate that the drug may be effective in delaying or preventing relapse in this patient population. Further, the data in our initial Phase I/II trial now are very mature." In that trial, 10 of 12 patients, or 83 percent, remain in complete remission with a median time from transplant of 33 months. Dr. Epstein explains, "Only 30-50 percent of ABMT patients would be expected to be free of disease after two years." In the subsequent Phase II trial, 32 of 41 patients currently evaluable, or 78 percent, remain in remission. The median time from transplant for these patients is 16 months.
 "Based on the observations in these trials, in 1993 we began a pivotal, Phase III trial of Oncolysin B in ABMT patients," says Epstein. "Because the two-year rate of relapse in ABMT patients is high," she adds, "the readout of data in this trial will be rapid as compared to the equivalent study of all lymphoma patients in remission, whose relapse rate is of the same magnitude but occurs over a longer time."
 Epstein further explains that "Because the transplantation procedure is effective in getting patients with different stages and types of disease into a complete remission, ABMT patients also serve as a model for all B-cell lymphoma patients in complete remission. Despite this heroic therapy, residual disease, though undetectable, still lingers in most patients. We are testing the use of our drug to eliminate residual disease which proliferates and leads to relapse." There are over 36,000 new cases of B-cell lymphoma in the United States each year. While conventional chemotherapy and radiation therapy often are effective initially, these treatments cure less than 25 percent of patients.
 ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for the treatment of cancer. The company produces potent "immunoconjugates" consisting of toxins or drugs coupled to targeting agents which search out and destroy cancer cells. The company currently has four products in 26 completed or ongoing clinical trials.
 -0- 12/7/93
 /CONTACT: Mark Ratner, director, external communications of ImmunoGen, 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts, Missouri IN: MTC SU:

CM-DJ -- NE001 -- 1181 12/07/93 09:58 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 7, 1993
Words:472
Previous Article:BRADLEES ELECTS DR. JOHN A. CURRY TO BOARD OF DIRECTORS
Next Article:SNO COUNTRY REPORTS LATEST SKIING CONDITIONS INFORMATION
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters